Article Details
Retrieved on: 2022-06-05 13:41:28
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Updated results from the ELEVATE-TN phase 3 trial showed AstraZeneca's Calquence (acalabrutinib) maintained a statistically significant ...
Article found on: www.pharmacytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here